Resumen
FOXM1 is an oncogenic transcription factor that has been implicated in cancer progression, metastases, and chemotherapy resistance. Multiple small-molecule FOXM1 inhibitors have been studied in the lab, but none have made it to clinical trials. The aim of this review is to describe the studied combination therapies with FOXM1 inhibitors. We evaluated the synergistic role of FOXM1 inhibitors with chemotherapy and molecular-targeted therapies for cancer treatment. Small-molecule FOXM1 inhibitors are promising compounds whose therapeutic benefits can be applied to different pediatric and adult cancers.